ÂÜÀòÂÒÂ×

Alan Holmes has worked in the biopharmaceutical industry since 1998. Alan started as a Research Associate at UCL, then moved to the National Institute of Dental and Craniofacial Research-NIH as a Visiting Fellow. In 2006, they joined Novartis as a Group Leader - Respiratory and was awarded the Novartis Presidential Postdoctoral Fellowship. In 2011, they returned to UCL as a Molecular Pharmacology (Drug Discovery) Group Leader- Translational Research Office, where they established a biology drug discovery group and led translation programs across a broad range of disease modalities. In 2014, they became an Organising Committee Member for the International Workshop on Cardiovascular Biology & Translational Medicine. In 2017, they joined BerGenBio ASA as an Associate Director Non-Oncology. Alan then moved to GSK in 2018 as a Director, Pulmonary Vascular Injury and Fibrosis DPU and became a Professor (Honorary), Associate Professor (Honorary) and Senior Lecturer (Honorary) at UCL. Lastly, in 2019, they joined UCB as a Director, Immunology TA and in 2021 they joined Engitix Therapeutics as Vice President Fibrosis and Senior Director, Fibrosis.

Alan Holmes obtained their BSc in Biology/Biological Sciences from the University of Leicester between 1990 and 1993. Alan then went on to pursue a PhD in Molecular mechanisms that contribute to fibrosis in scleroderma at UCL from 2000 to 2006.